Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Parkinson’s Disease Drugs market report explains the definition, types, applications, major countries, and major players of the Parkinson’s Disease Drugs market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
GlaxoSmithKline
Impax Laboratories
STADA Arzneimittel
F Hoffmann-La Roche
UCB Inc
Valeant Pharmaceuticals International
AbbVie
Merck
Novartis
Teva Pharmaceutical Industries
By Type:
Oral
Transdermal
Subcutaneous
Intestinal Infusion
By End-User:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Parkinson’s Disease Drugs Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Parkinson’s Disease Drugs Outlook to 2028- Original Forecasts
-
2.2 Parkinson’s Disease Drugs Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Parkinson’s Disease Drugs Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Parkinson’s Disease Drugs Market- Recent Developments
-
6.1 Parkinson’s Disease Drugs Market News and Developments
-
6.2 Parkinson’s Disease Drugs Market Deals Landscape
7 Parkinson’s Disease Drugs Raw Materials and Cost Structure Analysis
-
7.1 Parkinson’s Disease Drugs Key Raw Materials
-
7.2 Parkinson’s Disease Drugs Price Trend of Key Raw Materials
-
7.3 Parkinson’s Disease Drugs Key Suppliers of Raw Materials
-
7.4 Parkinson’s Disease Drugs Market Concentration Rate of Raw Materials
-
7.5 Parkinson’s Disease Drugs Cost Structure Analysis
-
7.5.1 Parkinson’s Disease Drugs Raw Materials Analysis
-
7.5.2 Parkinson’s Disease Drugs Labor Cost Analysis
-
7.5.3 Parkinson’s Disease Drugs Manufacturing Expenses Analysis
8 Global Parkinson’s Disease Drugs Import and Export Analysis (Top 10 Countries)
-
8.1 Global Parkinson’s Disease Drugs Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Parkinson’s Disease Drugs Export by Region (Top 10 Countries) (2017-2028)
9 Global Parkinson’s Disease Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Parkinson’s Disease Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Oral Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Transdermal Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Subcutaneous Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Intestinal Infusion Consumption and Growth Rate (2017-2022)
-
9.2 Global Parkinson’s Disease Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Pharmacy Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Retail Pharmacy Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Online Pharmacy Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Parkinson’s Disease Drugs Market Analysis and Outlook till 2022
-
10.1 Global Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.2.2 Canada Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.2.3 Mexico Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.3.2 UK Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.3.3 Spain Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.3.4 Belgium Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.3.5 France Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.3.6 Italy Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.3.7 Denmark Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.3.8 Finland Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.3.9 Norway Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.3.10 Sweden Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.3.11 Poland Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.3.12 Russia Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.3.13 Turkey Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.4.2 Japan Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.4.3 India Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.4.4 South Korea Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.4.5 Pakistan Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.4.6 Bangladesh Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.4.7 Indonesia Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.4.8 Thailand Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.4.9 Singapore Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.4.10 Malaysia Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.4.11 Philippines Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.4.12 Vietnam Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.5.2 Colombia Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.5.3 Chile Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.5.4 Argentina Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.5.5 Venezuela Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.5.6 Peru Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.5.7 Puerto Rico Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.5.8 Ecuador Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.6.2 Kuwait Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.6.3 Oman Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.6.4 Qatar Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.6.5 Saudi Arabia Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.6.6 United Arab Emirates Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.7.2 South Africa Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.7.3 Egypt Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.7.4 Algeria Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Parkinson’s Disease Drugs Consumption (2017-2022)
-
10.8.2 New Zealand Parkinson’s Disease Drugs Consumption (2017-2022)
11 Global Parkinson’s Disease Drugs Competitive Analysis
-
11.1 GlaxoSmithKline
-
11.1.1 GlaxoSmithKline Company Details
-
11.1.2 GlaxoSmithKline Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 GlaxoSmithKline Parkinson’s Disease Drugs Main Business and Markets Served
-
11.1.4 GlaxoSmithKline Parkinson’s Disease Drugs Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Impax Laboratories
-
11.2.1 Impax Laboratories Company Details
-
11.2.2 Impax Laboratories Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Impax Laboratories Parkinson’s Disease Drugs Main Business and Markets Served
-
11.2.4 Impax Laboratories Parkinson’s Disease Drugs Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 STADA Arzneimittel
-
11.3.1 STADA Arzneimittel Company Details
-
11.3.2 STADA Arzneimittel Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 STADA Arzneimittel Parkinson’s Disease Drugs Main Business and Markets Served
-
11.3.4 STADA Arzneimittel Parkinson’s Disease Drugs Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 F Hoffmann-La Roche
-
11.4.1 F Hoffmann-La Roche Company Details
-
11.4.2 F Hoffmann-La Roche Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 F Hoffmann-La Roche Parkinson’s Disease Drugs Main Business and Markets Served
-
11.4.4 F Hoffmann-La Roche Parkinson’s Disease Drugs Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 UCB Inc
-
11.5.1 UCB Inc Company Details
-
11.5.2 UCB Inc Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 UCB Inc Parkinson’s Disease Drugs Main Business and Markets Served
-
11.5.4 UCB Inc Parkinson’s Disease Drugs Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Valeant Pharmaceuticals International
-
11.6.1 Valeant Pharmaceuticals International Company Details
-
11.6.2 Valeant Pharmaceuticals International Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Valeant Pharmaceuticals International Parkinson’s Disease Drugs Main Business and Markets Served
-
11.6.4 Valeant Pharmaceuticals International Parkinson’s Disease Drugs Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 AbbVie
-
11.7.1 AbbVie Company Details
-
11.7.2 AbbVie Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 AbbVie Parkinson’s Disease Drugs Main Business and Markets Served
-
11.7.4 AbbVie Parkinson’s Disease Drugs Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Merck
-
11.8.1 Merck Company Details
-
11.8.2 Merck Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Merck Parkinson’s Disease Drugs Main Business and Markets Served
-
11.8.4 Merck Parkinson’s Disease Drugs Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Novartis
-
11.9.1 Novartis Company Details
-
11.9.2 Novartis Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Novartis Parkinson’s Disease Drugs Main Business and Markets Served
-
11.9.4 Novartis Parkinson’s Disease Drugs Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Teva Pharmaceutical Industries
-
11.10.1 Teva Pharmaceutical Industries Company Details
-
11.10.2 Teva Pharmaceutical Industries Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Teva Pharmaceutical Industries Parkinson’s Disease Drugs Main Business and Markets Served
-
11.10.4 Teva Pharmaceutical Industries Parkinson’s Disease Drugs Product Portfolio
-
11.10.5 Recent Research and Development Strategies
12 Global Parkinson’s Disease Drugs Market Outlook by Types and Applications to 2028
-
12.1 Global Parkinson’s Disease Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Oral Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Transdermal Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Subcutaneous Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Intestinal Infusion Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Parkinson’s Disease Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospital Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Retail Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Online Pharmacy Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Parkinson’s Disease Drugs Market Analysis and Outlook to 2028
-
13.1 Global Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.2.2 Canada Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.2.3 Mexico Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.3.2 UK Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.3.3 Spain Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.3.4 Belgium Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.3.5 France Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.3.6 Italy Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.3.7 Denmark Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.3.8 Finland Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.3.9 Norway Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.3.10 Sweden Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.3.11 Poland Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.3.12 Russia Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.3.13 Turkey Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.4.2 Japan Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.4.3 India Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.4.4 South Korea Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.4.8 Thailand Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.4.9 Singapore Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.4.11 Philippines Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.5.2 Colombia Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.5.3 Chile Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.5.4 Argentina Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.5.6 Peru Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.6.3 Oman Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.6.4 Qatar Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.7.2 South Africa Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.7.3 Egypt Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.7.4 Algeria Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Parkinson’s Disease Drugs Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Parkinson’s Disease Drugs
-
Figure of Parkinson’s Disease Drugs Picture
-
Table Global Parkinson’s Disease Drugs Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Parkinson’s Disease Drugs Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Oral Consumption and Growth Rate (2017-2022)
-
Figure Global Transdermal Consumption and Growth Rate (2017-2022)
-
Figure Global Subcutaneous Consumption and Growth Rate (2017-2022)
-
Figure Global Intestinal Infusion Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Pharmacy Consumption and Growth Rate (2017-2022)
-
Figure Global Retail Pharmacy Consumption and Growth Rate (2017-2022)
-
Figure Global Online Pharmacy Consumption and Growth Rate (2017-2022)
-
Figure Global Parkinson’s Disease Drugs Consumption by Country (2017-2022)
-
Table North America Parkinson’s Disease Drugs Consumption by Country (2017-2022)
-
Figure United States Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Canada Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Mexico Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Parkinson’s Disease Drugs Consumption by Country (2017-2022)
-
Figure Germany Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure UK Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Spain Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Belgium Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure France Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Italy Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Denmark Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Finland Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Norway Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Sweden Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Poland Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Russia Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Turkey Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Table APAC Parkinson’s Disease Drugs Consumption by Country (2017-2022)
-
Figure China Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Thailand Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Singapore Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Philippines Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Table South America Parkinson’s Disease Drugs Consumption by Country (2017-2022)
-
Figure Brazil Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Colombia Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Chile Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Argentina Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Peru Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Table GCC Parkinson’s Disease Drugs Consumption by Country (2017-2022)
-
Figure Bahrain Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Oman Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Qatar Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Table Africa Parkinson’s Disease Drugs Consumption by Country (2017-2022)
-
Figure Nigeria Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Africa Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Egypt Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure Algeria Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Table Oceania Parkinson’s Disease Drugs Consumption by Country (2017-2022)
-
Figure Australia Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Parkinson’s Disease Drugs Consumption and Growth Rate (2017-2022)
-
Table GlaxoSmithKline Company Details
-
Table GlaxoSmithKline Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline Parkinson’s Disease Drugs Main Business and Markets Served
-
Table GlaxoSmithKline Parkinson’s Disease Drugs Product Portfolio
-
Table Impax Laboratories Company Details
-
Table Impax Laboratories Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Impax Laboratories Parkinson’s Disease Drugs Main Business and Markets Served
-
Table Impax Laboratories Parkinson’s Disease Drugs Product Portfolio
-
Table STADA Arzneimittel Company Details
-
Table STADA Arzneimittel Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table STADA Arzneimittel Parkinson’s Disease Drugs Main Business and Markets Served
-
Table STADA Arzneimittel Parkinson’s Disease Drugs Product Portfolio
-
Table F Hoffmann-La Roche Company Details
-
Table F Hoffmann-La Roche Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table F Hoffmann-La Roche Parkinson’s Disease Drugs Main Business and Markets Served
-
Table F Hoffmann-La Roche Parkinson’s Disease Drugs Product Portfolio
-
Table UCB Inc Company Details
-
Table UCB Inc Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table UCB Inc Parkinson’s Disease Drugs Main Business and Markets Served
-
Table UCB Inc Parkinson’s Disease Drugs Product Portfolio
-
Table Valeant Pharmaceuticals International Company Details
-
Table Valeant Pharmaceuticals International Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Valeant Pharmaceuticals International Parkinson’s Disease Drugs Main Business and Markets Served
-
Table Valeant Pharmaceuticals International Parkinson’s Disease Drugs Product Portfolio
-
Table AbbVie Company Details
-
Table AbbVie Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table AbbVie Parkinson’s Disease Drugs Main Business and Markets Served
-
Table AbbVie Parkinson’s Disease Drugs Product Portfolio
-
Table Merck Company Details
-
Table Merck Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck Parkinson’s Disease Drugs Main Business and Markets Served
-
Table Merck Parkinson’s Disease Drugs Product Portfolio
-
Table Novartis Company Details
-
Table Novartis Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Parkinson’s Disease Drugs Main Business and Markets Served
-
Table Novartis Parkinson’s Disease Drugs Product Portfolio
-
Table Teva Pharmaceutical Industries Company Details
-
Table Teva Pharmaceutical Industries Parkinson’s Disease Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceutical Industries Parkinson’s Disease Drugs Main Business and Markets Served
-
Table Teva Pharmaceutical Industries Parkinson’s Disease Drugs Product Portfolio
-
Figure Global Oral Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Transdermal Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Subcutaneous Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Intestinal Infusion Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Retail Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Online Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Parkinson’s Disease Drugs Consumption Forecast by Country (2022-2028)
-
Table North America Parkinson’s Disease Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Parkinson’s Disease Drugs Consumption Forecast by Country (2022-2028)
-
Figure Germany Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Parkinson’s Disease Drugs Consumption Forecast by Country (2022-2028)
-
Figure China Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Parkinson’s Disease Drugs Consumption Forecast by Country (2022-2028)
-
Figure Brazil Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Parkinson’s Disease Drugs Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Parkinson’s Disease Drugs Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Parkinson’s Disease Drugs Consumption Forecast by Country (2022-2028)
-
Figure Australia Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Parkinson’s Disease Drugs Consumption Forecast and Growth Rate (2022-2028)
-
